1School of Pharmacy, Mohan Babu University, Sree Sainath Nagar, Tirupati, Andhra Pradesh 517102.
2School of Pharmacy, Mohan Babu University, Sree Sainath Nagar, Tirupati, Andhra Pradesh 517102.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that poses a major challenge in the treatment as it is recurring and conventional treatments have limitations. The delivery of drugs in targeted form, especially the application of biodegradable nanoparticles therapy, can be hopeful in the future to increase the therapeutic effects and reduce the side effects. In this review, the authors have given a detailed account of the current developments in the field of biodegradable nanoparticles used in delivery of targeted drugs to treat ulcerative colitis. We discuss several categories of biodegradable nanoparticles, such as liposomes, polymeric nanoparticles, and nanogels with references to their benefits in biocompatibility, controlled drug release, and delivery to inflamed colonic tissues. Moreover, the review addresses the design, modification techniques of surfaces, and action mechanisms of nanoparticles which increase specificity to UC lesions. Clinical potential of these nanoparticles is also assessed by the article, identifying the problems, regulatory issues and future perspectives of clinical translations of these nanoparticles. Through the synthesis of existing literature, we give an insight into the possibility of biodegradable nanoparticles to transform the treatment of ulcerative colitis into the new stage of personalized and effective therapeutic interventions.
Keywords: Biodegradable Nanoparticles, Targeted Drug Delivery, Ulcerative Colitis, Controlled Release, Nanomedicine, Polymeric Nanoparticles, Liposomes, Nanogels, Inflammatory Bowel Disease, Drug Targeting Strategies, Colonic Drug Delivery, Therapeutic Nanocarriers.
How to cite this article: Bathula B, Varalaxmi S. Advancements In Biodegradable Nanoparticles for Targeted Drug Delivery: A Comprehensive Review on Ulcerative Colitis Treatment. Int J Drug Deliv Technol. 2026;16(15s): 514-522. DOI: 10.25258/ijddt.16.15s.61
Source of support: Nil.
Conflict of interest: None